Overview

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Status:
Completed
Trial end date:
2017-04-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Androgens
Relugolix